{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang H"],"funding":["NCI NIH HHS","NIH","NIGMS NIH HHS"],"pagination":["e003339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8705233"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(12)"],"pubmed_abstract":["<h4>Background</h4>Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy.<h4>Methods</h4>We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies.<h4>R"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function."],"pmcid":["PMC8705233"],"funding_grant_id":["CA114046","P50 CA261608","Tara Miller Melanoma Foundation","P30 CA016672","P30 CA010815","P01 CA114046","R35 GM141832","P50 CA174523","CA170340"],"pubmed_authors":["Zhang G","Mitchell TC","Fan Y","Herlyn M","Zhang J","Somasundaram R","Connelly T","Guo W","Dong L","Wang H","Chen H","Liu S","Huang L","Li L","Scholler J","Choi R","June CH","Lu H","Ou L","Yeye G","Tian S","Huang A","Xu X","Mills GB"],"additional_accession":[]},"is_claimable":false,"name":"Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.","description":"<h4>Background</h4>Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy.<h4>Methods</h4>We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies.<h4>R","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-06-17T06:26:07.206Z","creation":"2022-02-11T15:11:43.237Z"},"accession":"S-EPMC8705233","cross_references":{"pubmed":["34937742"],"doi":["10.1136/jitc-2021-003339"]}}